Amarin Corp Plc (AMRN)

[BioChica]

Thank you! All valid points. I have mention that it is important for STRENGTH trial to show RRR, at least enough for some benefit, 8% would be fine, since it surley raised EPA blood serum levels. But not enough to produce the higher levels of RRR seen in REDUCE-IT trial. While still validating O3 EPA trials, yet not enough to compete with Vascepa. This will close the chapter for DHA as far as a CVD risk reducer.